

EMERGENCY CONDITIONS IN COVID-19 PATHOPHYSIOLOGICAL MECHANISMS, CLINICAL MANIFESTATIONS, DIAGNOSTIC CHALLENGES AND MANAGEMENT STRATEGIES - AN EXPANDED REVIEW

<https://doi.org/10.5281/zenodo.18008233>

Sadullayev S.E., Ibragimov S.J., Bobojonov Y.B.
Urgench State Medical Institute, Urgench, Uzbekistan.

E-mail: sadullayev.siroje@gmail.com

<https://orcid.org/0009-0006-4052-7183>

Abstract

Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is associated with a wide range of clinical presentations, including numerous emergency and life-threatening conditions. Acute hypoxemic respiratory failure, acute respiratory distress syndrome (ARDS), thromboembolic complications, septic shock, acute cardiac injury, and neurological emergencies represent the most critical manifestations requiring immediate medical intervention. These emergency conditions significantly contribute to intensive care unit admissions and mortality worldwide. This expanded review aims to provide an in-depth analysis of COVID-19-related emergency conditions, emphasizing their pathophysiological mechanisms, clinical features, diagnostic approaches, and current management strategies. Understanding these critical conditions is essential for improving emergency care, reducing mortality, and optimizing outcomes during ongoing and future pandemics.

Keywords

COVID-19, emergency medicine, ARDS, thromboembolism, septic shock, acute cardiac injury, review

Introduction. Since the onset of the COVID-19 pandemic, emergency departments and intensive care units have faced unprecedented challenges due to the rapid influx of critically ill patients. While the majority of SARS-CoV-2 infections result in mild or moderate disease, a substantial proportion of patients develop severe and rapidly progressive complications requiring urgent medical care. COVID-19 has revealed itself as a multisystem disease rather than a purely respiratory infection. The virus induces profound immune dysregulation, endothelial dysfunction, and coagulation abnormalities, leading to acute organ

failure. Emergency conditions associated with COVID-19 often develop suddenly and progress rapidly, leaving limited time for intervention.

This review provides a comprehensive and expanded overview of the most significant emergency conditions in COVID-19, integrating current evidence on pathophysiology, clinical presentation, diagnosis, and management strategies relevant to emergency and critical care practice.

Materials and Methods. This narrative review was conducted through an extensive search of peer-reviewed literature published between 2020 and 2024. Databases including PubMed, Scopus, and Google Scholar were searched using the keywords: “COVID-19,” “emergency conditions,” “ARDS,” “thromboembolism,” “septic shock,” “acute cardiac injury,” and “critical illness.”

Original research articles, systematic reviews, meta-analyses, and international guidelines were included. Emphasis was placed on studies describing acute and life-threatening complications of COVID-19 in adult patients. Data were synthesized qualitatively and organized into thematic sections.

Results

1. Acute Hypoxemic Respiratory Failure and ARDS. Acute hypoxemic respiratory failure is the most common emergency presentation in severe COVID-19. Patients often present with severe dyspnea, tachypnea, and hypoxemia that may be disproportionate to clinical signs, a phenomenon referred to as “silent hypoxia.”

COVID-19-related ARDS differs from classical ARDS in several aspects. In early stages, lung compliance may be relatively preserved despite profound hypoxemia. The underlying mechanisms include diffuse alveolar damage, pulmonary microthrombosis, endothelial injury, and excessive inflammatory responses.

Emergency management focuses on rapid oxygen supplementation, high-flow nasal oxygen, non-invasive ventilation, and timely escalation to invasive mechanical ventilation when necessary. Lung-protective ventilation strategies are essential to minimize ventilator-induced lung injury.

2. Thromboembolic Emergencies. Thromboembolic complications represent a major cause of morbidity and mortality in COVID-19. Pulmonary embolism, deep vein thrombosis, ischemic stroke, and acute coronary syndromes are frequently reported, particularly in critically ill patients. COVID-19-associated coagulopathy is characterized by elevated D-dimer levels, fibrin degradation products, and prolonged coagulation times. Endothelial inflammation, platelet activation, and cytokine-mediated coagulation cascade activation contribute to a hypercoagulable state. Early recognition of thrombotic events in emergency settings is challenging

due to overlapping clinical symptoms. Prompt imaging, laboratory evaluation, and initiation of anticoagulation therapy are critical components of management.

3. Septic Shock and Systemic Inflammatory Response. Septic shock is among the most severe emergency conditions associated with COVID-19. It is characterized by persistent hypotension, tissue hypoperfusion, and metabolic acidosis despite adequate fluid resuscitation. The pathogenesis involves an uncontrolled immune response, commonly referred to as a cytokine storm, leading to widespread endothelial damage, capillary leak, and multi-organ dysfunction. Elevated inflammatory markers such as interleukin-6, ferritin, and C-reactive protein are frequently observed. Emergency management requires early hemodynamic stabilization, vasopressor support, organ support, and prompt treatment of secondary bacterial infections.

4. Acute Cardiac Emergencies. Cardiac involvement is a critical aspect of COVID-19-related emergencies. Acute myocardial injury, myocarditis, arrhythmias, and acute heart failure have been documented in a significant proportion of hospitalized patients. Potential mechanisms include direct viral myocardial invasion, hypoxia-induced injury, microvascular thrombosis, and systemic inflammation. Elevated troponin levels are associated with poor prognosis and increased mortality. Emergency evaluation includes electrocardiography, cardiac biomarkers, and echocardiography. Management often requires multidisciplinary collaboration between emergency physicians, cardiologists, and intensivists.

5. Neurological Emergency Conditions. Neurological emergencies such as acute ischemic stroke, encephalopathy, seizures, and intracranial hemorrhage have been increasingly reported in COVID-19 patients. These complications are likely related to hypercoagulability, endothelial dysfunction, and systemic inflammation.

Stroke in COVID-19 often affects younger patients and may involve large vessels. Rapid neurological assessment and timely reperfusion therapy remain essential despite infection control challenges.

Discussion. Emergency conditions in COVID-19 reflect the systemic and complex nature of SARS-CoV-2 infection. The coexistence of respiratory failure, thrombosis, shock, and cardiac injury creates diagnostic and therapeutic challenges in emergency settings.

Delayed presentation, rapid clinical deterioration, and limited healthcare resources further complicate management. Early identification of high-risk patients, standardized emergency protocols, and continuous training of emergency personnel are essential to improve outcomes.

Conclusion. COVID-19-associated emergency conditions remain a major contributor to global morbidity and mortality. Acute respiratory failure, thromboembolic events, septic shock, cardiac and neurological emergencies require immediate recognition and aggressive management. A deep understanding of the underlying pathophysiological mechanisms is essential for optimizing emergency care and preparing healthcare systems for future pandemics.

REFERENCES:

1. World Health Organization. *Clinical management of COVID-19*. WHO; 2020.
2. Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, transmission, diagnosis, and treatment of COVID-19. *JAMA*. 2020;324:782–793.
3. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with SARS-CoV-2. *Lancet*. 2020;395:497–506.
4. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of COVID-19. *Lancet*. 2020;395:1054–1062.
5. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of COVID-19 in China. *N Engl J Med*. 2020;382:1708–1720.
6. Tang N, Li D, Wang X, et al. Abnormal coagulation parameters in patients with COVID-19. *J Thromb Haemost*. 2020;18:844–847.
7. Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis in COVID-19. *N Engl J Med*. 2020;383:120–128.
8. Bobojanov, Y. B., & Qadirova, N. I. (2025). MODERN TREATMENT APPROACHES FOR EPULIS: FROM CONVENTIONAL TO ADVANCED TECHNIQUES. *Multidisciplinary Journal of Science and Technology*, 5(6), 787-791.
9. Bobojanov, Y. B., & Qadirova, N. I. (2025). THE IMPACT OF COVID-19 ON THE DEVELOPMENT OF DENTAL DISEASES. *Multidisciplinary Journal of Science and Technology*, 5(6), 792-795.
10. Ибрагимов, С., Бобожонов, Ё., Курбанова, Н., & Сапаев, А. (2023). ОЦЕНКА СПЕЦИФИЧЕСКОГО ИММУНИТЕТА ПОСЛЕ ВАКЦИНАЦИИ ПРОТИВ НОВОЙ КОРОНАВИРУСНОЙ ИНФЕКЦИИ COVID-19. *Евразийский журнал медицинских и естественных наук*, 3(6), 117-120.
11. Хасанова Мохира Фархадовна (2023). ПЕРВОСТЕПЕННЫЕ ПРОБЛЕМЫ ОБУЧЕНИЯ СТУДЕНТОВ В МЕДИЦИНСКОМ ВУЗЕ ПРЕДМЕТА ФТИЗИАТРИЯ НА ПРИМЕРЕ УРГЕНЧСКОГО ФИЛИАЛА ТАШКЕНТСКОЙ МЕДИЦИНСКОЙ АКАДЕМИИ. *International scientific review*, (ХСII), 11-14.

12. Khasanova, M. F., & Farkhadovna, K. M. (2022). Course of Tuberculosis in Combination with Arterial Hypertension. *International Journal on Orange Technologies*, 4(1), 69-73.
13. ХАСАНОВА, М. НАУКА И ОБРАЗОВАНИЕ СЕГОДНЯ. *НАУКА И ОБРАЗОВАНИЕ СЕГОДНЯ*, (4), 55-58.
14. Хасанова, М. Ф., & Юсупов, Ш. Р. (2025). Особенности течения первичных форм туберкулеза у детей и подростков. *Academy-2025 год*, (2), 82.
15. Хасанова, М. Ф., & Юсупов, Ш. Р. (2025). Современные аспекты лечения больных кавернозным туберкулезом. *Вестник науки и образования*, 107-109.
16. Атаджанова, О. Н., & Хасанова, М. Ф. (2024). ПЕРСПЕКТИВА ПРИМЕНЕНИЯ ФИТОТЕРАПИИ У БОЛЬНЫХ ТУБЕРКУЛЕЗОМ ЛЕГКИХ. *Вестник науки и образования*, (1 (144)-2), 73-77.
17. Хасанова, М. Ф., & Юсупов, Ш. Р. (2024). Изучение иммунологических аспектов диагностики аллергического бронхита у больных туберкулезом легких. *Academy*, (4 (80)), 23-27.
18. Хасанова, М. Ф. Диагностика аллергического бронхита с иммунологическими изменениями у больных туберкулезом. *European research*, (4), 81.
19. Хасанова, М. Ф. (2021). Опасность туберкулеза с сочетанной вич-инфекцией. *European science*, (6 (62)), 46-50.
20. Хасанова, М. Ф. (2023). ПЕРСПЕКТИВЫ РАЗВИТИЯ СПОРТА СРЕДИ СТУДЕНТОВ ТАШКЕНТСКОЙ МЕДИЦИНСКОЙ АКАДЕМИИ УРГЕНЧСКОГО ФИЛИАЛА. *Журнал Наука, техника и образование*, 83-86.
21. Аскарлова, Р. И., Юсупов, Ш. Р., & Хасанова, М. Ф. (2023). Атаджанова ОН Основные меры профилактики населения Приаралья от туберкулеза для детей и подростков. *Проблемы современной науки и образования*, (7), 185.
22. Хасанова, М. Ф. (2023). Эффективность Арт терапии для развития эмоционального интеллекта пожилых пациентов больных туберкулезом. *Вестник науки и образования*, (1 (132)-1), 99-102.
23. Хасанова, М. Ф., Атаджанова, О. Н., & Худойберганов, Р. Т. (2024). Сравнительный анализ социальных, экономических факторов развития туберкулеза среди подростков школьного возраста. *Вестник науки и образования*, (4 (147)-2), 92-96.
24. Атаджанова, О. Н., Юсупов, Ш. Р., & Хасанова, М. Ф. (2024). Анализ социальных, экономических факторов развития туберкулеза среди подростков школьного возраста. *ВЕСТНИК НАУКИ И ОБРАЗОВАНИЯ*, 65-67.

25. Хасанова, М. Ф. (2024). Особенности формирования иммунологического ответа при аллергическом бронхите у больных туберкулезом легких. *Наука и образование сегодня*, (4 (81)), 55-58.
26. Атаджанова, О. Н., Хасанова, М. Ф., Юсупов, Ш. Р., & Аскарлова, Р. И. (2024). Туберкулез у пациентов преклонного возраста на этапе стационарного ведения больных. *Вестник науки и образования*, (4 (147)-1), 65-68.
27. Каюмов, У. К., Хатамова, Д. Т., Саипова, М. Л., Бадритдинова, М. Н., Алимов, С. С., & Исмаилов, К. Я. (2007). Продолжительность болевого приступа у больных ишемической болезнью сердца при наличии отдельных компонентов метаболического синдрома. *Кардиология Узбекистана*, (3), 47-50.
28. Ismailov, K. Y., & Djabbarova, Z. I. (2024). OBESITY AND ISCHEMIC HEART DISEASE. *European Journal of Modern Medicine and Practice*, 4(11), 364-367.
29. Ismailov, K. Y. (2017). Means to detect harmful for children content and measures to prevent its spread. In *International Scientific and Practical Conference World Science* (Vol. 1, No. 4, pp. 15-17). ROST.
30. Исмоилова Зиёда Актамовна, Юлдашев Ботир Ахматович, & Ахматов Аблокул Ахматович (2019). Хронический пиелонефрит у детей на фоне нарушенного обмена мочевой кислоты: особенности анамнеза и клиничко-лабораторная характеристика. *Вопросы науки и образования*, (4 (49)), 165-176.
31. Ахмеджанова Наргиза Исмаиловна, Ахмеджанов Исмаил Ахмеджанович, Исмоилова Зиёда Актамовна, & Гаппарова Гули Нурмуминовна (2023). Оценка функционального состояния почек при ренальных осложнениях у детей в период пандемии COVID-19: обсервационное когортное ретроспективное клиническое исследование. *Кубанский научный медицинский вестник*, 30 (3), 25-33. doi: 10.25207/1608-6228-2023-30-3-25-33
32. Исмоилова, З. А., Тажиева, З. Б., & Ражабова, Н. Т. COVID-19 ЎТКАЗГАН БОЛАЛАРДА ЎТКИР БУЙРАК ШИКАСТЛАНИШИНИ ҚИЁСИЙ БАҲОЛАШ. ДОКТОР АХБОРОТНОМАСИ ВЕСТНИК ВРАЧА DOCTOR'S HERALD, 72.
33. Исмоилова Зиёда Актамовна, & Ахматов Аблокул Ахматович (2019). Состояние сердечно сосудистой системы у детей с хроническим пиелонефритом на фоне гиперурикемии. *Вопросы науки и образования*, (4 (49)), 177-185.
34. Ismoilova, Z. A., & Ahmedjanova, N. I. (2023). The role of lipocalin-2 associated with neutrophil gelatinase (ngal) in the development of acute nephrological pathology in children against the background of covid-19. *European*

International Journal of Multidisciplinary Research and Management Studies, 3(06), 151-156.

35. Aktamovna, I. Z., Ismoilovna, A. N., & Sajid, M. A. A. (2022). Clinic and laboratory characteristics of acute kidney failure in children during the COVID-19 pandemic.

36. Aktamovna, I. Z., Abdullayevna, K. T., & Sajid, M. A. A. (2022). Comparative assessment of renal complications in children during the COVID-19 pandemic.

37. Klicheva T.A., & Ismailova Z.A. (2021). Allergy In Children With Atopic Dermatitis. *The American Journal of Medical Sciences and Pharmaceutical Research*, 3(01), 171–174. <https://doi.org/10.37547/TAJMSPR/Volume03Issue01-26>

38. Rajabova, N. T., Ismailova, Z. A., & Klicheva, T. A. (2021). The Effect Of Uric Acid Metabolism Disorders On The Cardiovascular System In Children With Pyelonephritis. *The American Journal of Medical Sciences and Pharmaceutical Research*, 3(01), 167-170.

39. Ismoilova, Z. A., & Ishankulova, N. N. (2021). Rational Use Of Drugs In The Comprehensive Treatment Of Bronchoobstructive Syndrome In Children. *The American Journal of Medical Sciences and Pharmaceutical Research*, 3(01), 175-178.

40. Ismailova, Z. A., Djumaniyazova, Z. F., Rajabova, N. T., Rajapov, A. A., & Yakubov, R. F. (2019). Condition of the cardiovascular system in children with chronic pyelone-phritis on the background of hyperuricemia. *International Journal of Advanced Science and Technology*, 28(14), 100-104.

41. Исмоилова, З. А., Тилавова, Ю. М., & Камариддинзода, М. К. (2019). ОСОБЕННОСТИ АНАМНЕЗА И КЛИНИКО-ЛАБОРАТОРНОЙ ХАРАКТЕРИСТИКИ ХРОНИЧЕСКОГО ПИЕЛОНЕФРИТА У ДЕТЕЙ НА ФОНЕ НАРУШЕННОГО ОБМЕНА МОЧЕВОЙ КИСЛОТЫ. In *Завадские чтения* (pp. 71-74).

42. Мехроджева, Ш., Юлдашев, Б., Ахматов, А., Ахматова, Ю., & Исмаилова, З. (2017). Клинико-лабораторная характеристика проявления нефротического синдрома у детей по данным специализированного нефрологического стационара. *Журнал вестник врача*, 1(2), 30-32.

43. Ismailov, K. Y., & Abdullaev, I. K. Research of the Distribution and Transmission of Covid-19 Infection. *JournalNX*, 686-691.

44. Ismailov, K. Y. (2025). THE FACTORS CAUSING ISCHEMIC HEART DISEASE AMONG THE POPULATION OF THE SOUTHERN ARAL SEA REGION HEVE BEEN STUDIED. *Journal of Multidisciplinary Innovation in Science and Education*, 1(2), 413-418.

45. Абдуллаев, И. К., Исмаилов, К. Я., Курбанов, С. Р., & Матякубов, Ж. Р. ТИББИЁТ ОЛИЙГОҲЛАРИДА ЖАМОАТ САЛОМАТЛИГИ ВА СОҒЛИҚНИ САҚЛАШНИ БОШҚАРИШ ФАНИНИ ЎҚУВ ДАСТУРИГА КУРС ИШИНИ КИРИШНИНГ АМАЛИЙ АҲАМИЯТИ. *Султанов ГН-ректор, д. м. н. Зам. главного редактора*, 31.
46. Ismailov, K. (2019). THEORETICAL-LEGAL APPROACHES TO THE PROBLEMS OF INFORMATION-ANALYTICAL ACTIVITIES OF THE NATIONAL POLICE AT THE MODERN STATE OF COOPERATION. *European Reforms Bulletin*, 109.
47. Bochkoviy, O., Khankevich, A., Boiko-Dzhumelia, V., Chichyan, O. O., Baadzhi, N. A., Zaiets, H. V., ... & Smolka, O. V. (2020). *European Reforms Bulletin*.
48. Jaloladdin o'g'li, M. M., & Ernazarovich, S. S. (2025). COMORBID INFECTIONS IN YOUNG CHILDREN: CLINICAL FEATURES AND ANALYSIS OF OBSERVATIONS. *Multidisciplinary Journal of Science and Technology*, 5(4), 362-366.
49. Ibraximova, H. R., & Sadullaev, S. E. (2025). THE EFFECT OF PROPER NUTRITION ON IMMUNITY IN CHILDREN. *Multidisciplinary Journal of Science and Technology*, 5(6), 1229-1233.
50. Sadullaev, M. S. S. M. S., & Sh, S. M. D. (2023). THE COURSE OF CORONAVIRUS AGAINST THE BACKGROUND OF CHRONIC HEPATITIS.
51. Туйчиев, Л. Н., Худайкулова, Г. К., Джураева, Н., & Эралиев, У. Э. (2023). A study of the factors affecting the effectiveness of COVID-19 rehabilitation.
52. Matkarimov, M., & Sadullaev, S. (2025). BOLALARDA INFEKSION MONONUKLEOZNING XUSUSIYATLARI. *Journal of science-innovative research in Uzbekistan*, 3(4), 169-177.
53. Ernazarovich, S. S., Zarifboyevich, O. S., Rustombekovich, N. R., & Kadamovna, A. D. (2025). DYNAMICS OF THE COVID-19 PANDEMIC AND ITS CLINICAL CONSEQUENCES. *Multidisciplinary Journal of Science and Technology*, 5(5), 85-90.
54. Kadamovna, A. D., Rustombekovich, N. R., Zarifboyevich, O. S., & Ernazarovich, S. S. (2025). COMBINATIONS OF HEPATITIS B WITH PULMONARY TUBERCULOSIS. *Multidisciplinary Journal of Science and Technology*, 5(5), 60-65.
55. Rustombekovich, N. R., Zarifboyevich, O. S., Kadamovna, A. D., & Ernazarovich, S. S. (2025). THE STATE OF THE ANTIOXIDANT DEFENSE SYSTEM IN CHRONIC HEPATITIS C. *Multidisciplinary Journal of Science and Technology*, 5(5), 79-84.

56. Артиков, И. А., Отажанов, Ш. З., & Садуллаев, С. Э. (2025). ПАТОМОРФОЛОГИЧЕСКИЕ АСПЕКТЫ ДЕТСКОГО ЛИМФОБЛАСТНОГО ЛЕЙКОЗА. *Multidisciplinary Journal of Science and Technology*, 5(6), 257-264.
57. Raximboyevich, Y. S., Rustamovna, I. H., Sabirovna, M. S., & Ernazarovich, S. S. (2025). CLINICAL FEATURES OF ESCHERICHIOSIS IN CHILDREN. *Multidisciplinary Journal of Science and Technology*, 5(6), 220-224.
58. Khusanov, A. M., Kh, N. A., & Sadullaev, S. E. (2024, March). THE STRUCTURE OF COMORBID PATHOLOGY IN CHILDREN WITH COVID-19. In *CONFERENCE ON THE ROLE AND IMPORTANCE OF SCIENCE IN THE MODERN WORLD* (Vol. 1, No. 2, pp. 27-28).
59. Ибраимова, Х. Р., Матъякубова, О. У., Садуллаев, С. Э., & Абдуллаева, Д. К. (2023). ГЕЛЬМИНТЫ У ДЕТЕЙ СРЕДИ НАСЕЛЕНИЯ УЗБЕКИСТАНА. *IMRAS*, 6(7), 323-327.
60. Sadullaev, S. E., Ibragimov, S. J., Bobojonov, Y. B., & Mamatqulov, T. T. (2025). INTESTINAL IMMUNITY. *Multidisciplinary Journal of Science and Technology*, 5(2), 485-488.
61. Sadullaev, S. E., Ibragimov, S. J., Bobojonov, Y. B., Yoqubov, Q. Y., Abdullayeva, D. K., & Khasanova, J. R. (2024). PREVALENCE OF DIARRHEAL DISEASES IN THE REPUBLIC OF UZBEKISTAN. *International Journal of Education, Social Science & Humanities*, 12(3), 356-363.
62. Sadullaev, S. E., Bobajanov, A. O., Khusinbayev, I. D., Durdiev, E. S., & Ismoilova, A. R. (2025). PSYCHOLOGICAL REHABILITATION DURING THE CORONAVIRUS PANDEMIC. *Multidisciplinary Journal of Science and Technology*, 5(2), 429-433.
63. Ералиев, У. Э., & Садуллаев, С. Э. (2020). Molecular genetic characteristics of rotavirus infection in children. *Молодой ученый*, (38), 46-48.
64. Ibrakhimova, H. R., Matyakubova, O. U., Sadullaev, S. E., & Abdullayeva, D. K. (2023). HELMINTISES IN CHILDREN AMONG THE POPULATION IN UZBEKISTAN. *IMRAS*, 6 (7), 323-327.
65. Artikov, I. A., Sadullaev, S. E., Ibrakhimova, H. R., & Abdullayeva, D. K. (2023). RELEVANCE OF VIRAL HEPATITIS EPIDEMIOLOGY. *IMRAS*, 6 (7), 316-322.
66. Masharipov, S., Sadullaev, S. E., & Sh, M. D. (2023). THE COURSE OF CORONAVIRUS AGAINST THE BACKGROUND OF CHRONIC HEPATITIS. *Научный импульс*, 78.
67. Sadullayev, S. E. (2024). THE COURSE OF NOSOCOMIAL PNEUMONIA IN PATIENTS ON LONG-TERM ARTIFICIAL LUNG

VENTILATION. *O'ZBEKISTONDA FANLARARO INNOVATSIYALAR VA ILMIY TADQIQOTLAR JURNALI*, 2(26), 80-84.

68. Tuychiev, L. N., Khudaykulova, G. K., Eraliev, U. E., Djuraeva, N. K., & Sadullaev, S. E. (2023). A STUDY OF THE FACTORS AFFECTING THE EFFECTIVENESS OF COVID-19 REHABILITATION.

69. Рахматуллаева, Ш. Б., Муминова, М. Т., Нурматов, А. Х., & Саъдуллаев, С. Э. (2023). Особенности течения COVID-19 у детей с коморбидной патологией. *Педиатрия. Восточная Европа*, (3 Часть 12), 436-442.

70. Sadullayev, S. E., Abdullayeva, D. K., Ibragimov, S. J., & Yoqubov, Q. Y. (2024). ANALYSIS OF THE EPIDEMIOLOGICAL FEATURES OF DIARRHEAL DISEASES IN CHILDREN IN THE SOUTHERN ARAL REGION. *Multidisciplinary Journal of Science and Technology*, 4(2), 345-351.

71. Сабировна, Ш., & Машарипова, А. И. А. Садуллаев Сирож Эрназарович, и Абдуллаева Дилфуза Кадамовна. 2022.«. ТЕЧЕНИЕ КОРОНАВИРУСНОЙ ИНФЕКЦИИ НА ФОНЕ ГЕПАТИТОВ». *Новости образования: исследование в XXI веке*, 1(5), 573-77.

72. Sadullayev, S. E., Matyakubova, O. U., Artikov, I. A., Nurllayev, R. R., Ibadullayeva, S. S., & Yakubov, K. Y. (2023). Results Of Studies On The Level Of Population Knowledge About Parasitic Diseases And Its Prevention. *Western European Journal of Medicine and Medical Science*, 1(4), 15-20.

73. Бобожанов, У. А., & Киличев, И. А. (2019). Структура эпилептических судорог у детей проживающих в зоне Приаралья. *Тиббиётда янги кун. Илмий рефератив, маърифий-маъновий журнал*, (3 (27)), 70.

74. Бобожанов, У., & Садикова, Г. (2023). Болаларда эпилепсиянинг келиб чиқиш сабаллари, ҳавф омиллари ва кечиши. *Неврология*, 1(2), 49-51. извлечено от <https://inlibrary.uz/index.php/nevrologiya/article/view/19687>

75. Бобожанов, У. А., & Садикова, Г. К. CLINICAL AND DIAGNOSTIC CHARACTERISTICS OF CHILDREN'S EPILEPSY LIVING IN THE ARAL SEA REGION.

76. Бобожанов, У. А., & Киличев, И. А. (2019). STRUCTURE OF EPILEPTIC VESSELS IN CHILDREN RESIDING IN THE AREAL REGION AREA. *Новый день в медицине*, (3), 70-72.

77. Бобожанов, У. А., & Киличев, И. А. (2018). Факторы риска спинальных аномалий у детей. *Национальный журнал неврологии*, (1), 50-53.

78. Садикова, Г. К., Таджиев, М. М., & Бобожанов, У. А. (2017). Анализ факторов риска спинальных аномалий у детей. *Молодой ученый*, (12), 151-153.

79. Kilichev, I. A., Matyokubov, M. O., Adambaev, Z. I., Khudayberganov, N. Y., & Mirzaeva, N. S. (2023). Register of stroke in the desert-steppe zones of Uzbekistan. In *BIO Web of Conferences* (Vol. 65, p. 04002). EDP Sciences.
80. Qilichev, I. A., Matmurodov, R. J., & Mirzaeva, N. S. (2020). Dynamics Of Neuropsychological Disorders In Patients With Light Cranio-Brain Injury. *Solid State Technology*, 63(6), 15202-15209.
81. Taxirovich, J. M., Otajonovich, M. M., & Adilbekovich, B. U. (2025). SMOKING OF TOBACCO PRODUCTS AND STROKE RISK (A LITERATURE REVIEW). *ZA'MONAVIY TA'LIM ISLOHOTLARI VA ULARNING AMALIY YECHIMLARI: KONFERENSIYA MATERIALLARI*, 1(4), 61-65.
82. Бекметова, Ш. К., Мирзаева, Н. С., & Джуманиязова, Г. М. (2017). Течение и исход беременности у женщин с тяжелой внебольничной пневмонией. *Авиценна*, (7), 4-6.
83. Камалидинова, З. У., Мирзаева, Н. С., & Сатимова, Д. М. (2024). РОЛЬ НАПОЛНЕННЫХ ДЕСЕНСИТАЙЗЕРОВ С НЕМА В ТЕРАПИИ ЧУВСТВИТЕЛЬНОСТИ ЗУБОВ. *AMERICAN JOURNAL OF EDUCATION AND LEARNING*, 2(5), 949-952.
84. Киличев, И. А., Матмuroдov, Р. Ж., & Мирзаева, Н. С. (2020). FEATURES OF NEUROLOGICAL AND NEUROPSYCHOLOGICAL DISORDERS AFTER A LIGHT TRAUMATIC BRAIN INJURY. *Новый день в медицине*, (2), 137-141.
85. Мирзаева, Н. С. (2018). ПСИХОНЕВРОЛОГИЧЕСКИЕ НАРУШЕНИЯ В ОТДАЛЕННОМ ПЕРИОДЕ ЧЕРЕПНО-МОЗГОВОЙ ТРАВМЫ (ОБЗОР ЛИТЕРАТУРЫ). In *Современные медицинские исследования* (pp. 39-43).
86. Шамуратова, Г. Б., & Мирзаева, Н. С. (2017). ЧАСТОТА ВСТРЕЧАЕМОСТИ ФАКТОРОВ РИСКА ИНСУЛЬТА ВЗАВИСИМОСТИ ОТ ЛАТЕРАЛИЗАЦИИ ОЧАГА ПОРАЖЕНИЯ. *Национальный журнал неврологии*, 1(S11), 51-53.